The Adenosine Receptor A1 pipeline drugs market research report outlays comprehensive information on the Adenosine Receptor A1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Adenosine Receptor A1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Oncology, and Respiratory which include the indications Parkinson’s Disease, Alzheimer’s Disease, Unspecified Cardiovascular Disorders, Cardiac Arrest, Solid Tumor, Unspecified Cancer, Asthma, and Chronic Obstructive Pulmonary Disease (COPD). It also reviews key players involved in Adenosine Receptor A1 targeted therapeutics development with respective active and dormant or discontinued products.
The Adenosine Receptor A1 pipeline targets constitutes close to 15 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 1, 7, and 1 respectively. Similarly, the universities portfolio in IND/ CTA Filed, Preclinical, and Discovery comprises 1, 1, and 2 molecule.
Adenosine Receptor A1 overview
Adenosine receptor A1 (ADORA1) is a receptor for adenosine belongs to the G-protein coupled receptor 1 family. There are three types of adenosine receptors, each with a specific pattern of ligand binding and tissue distribution, and together they regulate a diverse set of physiologic functions. The type A1 receptors inhibit adenylyl cyclase and play a role in the fertilization process.
For a complete picture of Adenosine Receptor A1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
